We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Unexpectedly Requests Advisory Panel Meeting for FibroGen’s Anemia Drug
FDA Unexpectedly Requests Advisory Panel Meeting for FibroGen’s Anemia Drug
The FDA has suddenly decided to call for an advisory committee meeting to discuss San Francisco biotech FibroGen’s investigational anemia pill, roxadustat, late in its review process, a development that was not anticipated.